Page last updated: 2024-11-07

benzanthracene-3,4-dihydrodiol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

benzanthracene-3,4-dihydrodiol: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID107945
MeSH IDM0064210

Synonyms (10)

Synonym
3,4-dihydroxy-3,4-dihydrobenz(a)anthracene
benzo(a)anthracene-3,4-dihydrodiol
benzanthracene-3,4-dihydrodiol
3,4-dihydrobenz(a)anthracene-3,4-diol
60839-18-1
benz(a)anthracene-3,4-diol
benz(a)anthracene-3,4-diol, 3,4-dihydro-
3,4-dihydro-3,4-dihydroxybenzanthracene
DTXSID80976310
3,4-dihydrotetraphene-3,4-diol
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (50.00)18.7374
1990's4 (33.33)18.2507
2000's2 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]